Literature DB >> 21940902

Linkage of gut microbiome with cognition in hepatic encephalopathy.

Jasmohan S Bajaj1, Jason M Ridlon, Phillip B Hylemon, Leroy R Thacker, Douglas M Heuman, Sean Smith, Masoumeh Sikaroodi, Patrick M Gillevet.   

Abstract

Hepatic encephalopathy (HE) has been related to gut bacteria and inflammation in the setting of intestinal barrier dysfunction. We aimed to link the gut microbiome with cognition and inflammation in HE using a systems biology approach. Multitag pyrosequencing (MTPS) was performed on stool of cirrhotics and age-matched controls. Cirrhotics with/without HE underwent cognitive testing, inflammatory cytokines, and endotoxin analysis. Patients with HE were compared with those without HE using a correlation-network analysis. A select group of patients with HE (n = 7) on lactulose underwent stool MTPS before and after lactulose withdrawal over 14 days. Twenty-five patients [17 HE (all on lactulose, 6 also on rifaximin) and 8 without HE, age 56 ± 6 yr, model for end-stage liver disease score 16 ± 6] and ten controls were included. Fecal microbiota in cirrhotics were significantly different (higher Enterobacteriaceae, Alcaligeneceae, and Fusobacteriaceae and lower Ruminococcaceae and Lachnospiraceae) compared with controls. We found altered flora (higher Veillonellaceae), poor cognition, endotoxemia, and inflammation (IL-6, TNF-α, IL-2, and IL-13) in HE compared with cirrhotics without HE. In the cirrhosis group, Alcaligeneceae and Porphyromonadaceae were positively correlated with cognitive impairment. Fusobacteriaceae, Veillonellaceae, and Enterobacteriaceae were positively and Ruminococcaceae negatively related to inflammation. Network-analysis comparison showed robust correlations (all P < 1E-5) only in the HE group between the microbiome, cognition, and IL-23, IL-2, and IL-13. Lactulose withdrawal did not change the microbiome significantly beyond Fecalibacterium reduction. We concluded that cirrhosis, especially when complicated with HE, is associated with significant alterations in the stool microbiome compared with healthy individuals. Specific bacterial families (Alcaligeneceae, Porphyromonadaceae, Enterobacteriaceae) are strongly associated with cognition and inflammation in HE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940902      PMCID: PMC3345956          DOI: 10.1152/ajpgi.00190.2011

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  45 in total

1.  Immunomodulation: a new approach to the therapy of cirrhosis?

Authors:  Fabio Marra; Francesco Annunziato
Journal:  Gut       Date:  2010-07       Impact factor: 23.059

2.  Highlighting new phylogenetic specificities of Crohn's disease microbiota.

Authors:  S Mondot; S Kang; J P Furet; D Aguirre de Carcer; C McSweeney; M Morrison; P Marteau; J Doré; M Leclerc
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

3.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

Authors:  O Riggio; M Varriale; G P Testore; R Di Rosa; E Di Rosa; M Merli; A Romiti; C Candiani; L Capocaccia
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

4.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

Review 5.  Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club.

Authors:  F Wong; M Bernardi; R Balk; B Christman; R Moreau; G Garcia-Tsao; D Patch; G Soriano; J Hoefs; M Navasa
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  The microbiome-gut-brain axis: from bowel to behavior.

Authors:  J F Cryan; S M O'Mahony
Journal:  Neurogastroenterol Motil       Date:  2011-03       Impact factor: 3.598

Review 7.  Microbial community profiling for human microbiome projects: Tools, techniques, and challenges.

Authors:  Micah Hamady; Rob Knight
Journal:  Genome Res       Date:  2009-04-21       Impact factor: 9.043

8.  Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats.

Authors:  Ece Mutlu; Ali Keshavarzian; Phillip Engen; Christopher B Forsyth; Masoumeh Sikaroodi; Patrick Gillevet
Journal:  Alcohol Clin Exp Res       Date:  2009-07-23       Impact factor: 3.455

9.  Network-based modeling of the human gut microbiome.

Authors:  Ammar Naqvi; Huzefa Rangwala; Ali Keshavarzian; Patrick Gillevet
Journal:  Chem Biodivers       Date:  2010-05       Impact factor: 2.408

10.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.

Authors:  James Robert White; Niranjan Nagarajan; Mihai Pop
Journal:  PLoS Comput Biol       Date:  2009-04-10       Impact factor: 4.475

View more
  187 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

Review 2.  Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis.

Authors:  Ming Luo; Jian-Yang Guo; Wu-Kui Cao
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

3.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

Review 4.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

Review 5.  Probiotics and liver disease.

Authors:  Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal:  Perm J       Date:  2013

6.  The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.

Authors:  Puneet Puri; Suthat Liangpunsakul; Jeffrey E Christensen; Vijay H Shah; Patrick S Kamath; Gregory J Gores; Susan Walker; Megan Comerford; Barry Katz; Andrew Borst; Qigui Yu; Divya P Kumar; Faridoddin Mirshahi; Svetlana Radaeva; Naga P Chalasani; David W Crabb; Arun J Sanyal
Journal:  Hepatology       Date:  2018-02-22       Impact factor: 17.425

7.  Decompensated cirrhosis and microbiome interpretation.

Authors:  Jasmohan S Bajaj; Naga S Betrapally; Patrick M Gillevet
Journal:  Nature       Date:  2015-09-17       Impact factor: 49.962

Review 8.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 9.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Bile Acid 7α-Dehydroxylating Gut Bacteria Secrete Antibiotics that Inhibit Clostridium difficile: Role of Secondary Bile Acids.

Authors:  Jason D Kang; Christopher J Myers; Spencer C Harris; Genta Kakiyama; In-Kyoung Lee; Bong-Sik Yun; Keiichi Matsuzaki; Megumi Furukawa; Hae-Ki Min; Jasmohan S Bajaj; Huiping Zhou; Phillip B Hylemon
Journal:  Cell Chem Biol       Date:  2018-10-25       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.